Trial Group - Lung

locally advanced or metastatic non-small cell lung cancer previously treated with systemic cytotoxic therapy (or ineligible), and an immune checkpoint inhibitor (as monotherapy or in combination with systemic cytotoxic chemotherapy, or ineligible)

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2).

Advanced non-small cell lung cancer (NSCLC) who are at least 18 years of age.

This trial will investigate the utility of biomarker-based triage for patients with advanced non-small cell lung cancer (NSCLC) without prior systemic therapy.

Patients with advanced stage RET-rearranged NSCLC, treated with at least one platinum based systemic chemotherapy regimen.

The primary objective is to assess the efficacy of alectinib in terms of best overall response (OR) assessed by RECIST 1.1., from the start of trial treatment across all time points until the end of trial treatment

Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer

To assess the efficacy and safety of Pembrolizumab (MK-3475) with platinum doublet chemotherapy as neoadjuvant/adjuvant therapy for participants With resectable stage IIB or IIIA non-small cell lung cancer.